'BPSA,' a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia

Urology

Volumn 55, Issue 1, 2000, Pages 41-45

  Mikolajczyk, Stephen D ^a   Millar, Lisa S ^a   Wang, Tang J ^a   Rittenhouse, Harry G ^a   Wolfert, Robert L ^a   Marks, Leonard S ^b   Song, Weitao ^c   Wheeler, Thomas M ^c   Slawin, Kevin M ^c  

^a Hybritech Incorporated   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOAFFINITY CHROMATOGRAPHY; MALE; NODULAR HYPERPLASIA; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY;

HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA;

EID: 0033963210     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00372-6     Document Type: Article

References (22)

1. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 324:1991;1156-1161.
2. Oesterling J.E. Prostate-specific antigen a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate . J Urol. 145:1991;907-923.
3. Labrie F., Dupont A., Suburu R., et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol. 147:1992;846-851.
4. Rittenhouse H.G., Finlay J.A., Mikolajczyk S.D., et al. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA) two closely related, but distinct, kallikreins in the prostate . Crit Rev Clin Lab Sci. 35:1998;275-368.
5. Christensson A., Laurell C.B., Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 194:1990;755-763.
6. Zhang W.M., Leinonen J., Kalkkinen N., et al. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem. 41:1995;1567-1573.
7. Chen Z., Chen H., Stamey T.A. Prostate specific antigen in benign prostatic hyperplasia purification and characterization . J Urol. 157:1997;2166-2170.
8. Mikolajczyk S.D., Grauer L.S., Millar L.S., et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology. 50:1997;710-714.
9. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease a prospective multicenter clinical trial . JAMA. 279:1998;1542-1547.
10. Woodrum D.L., Brawer M.K., Partin A.W., et al. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol. 159:1998;5-12.
11. 1-antichymotrypsin. Clin Chem. 37:1991;1618-1625.
12. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer assay of the complex improves clinical sensitivity for cancer . Cancer Res. 51:1991;222-226.
13. Wheeler T.M., Lebovitz R.M. Fresh tissue harvest for research from prostatectomy specimens. Prostate. 25:1994;274-279.
14. Franks L.M. Benign nodular hyperplasia of the prostate a review . Ann R Coll Surg Engl. 14:1954;92-106.
15. Wang T.J., Linton H.J., Sokoloff R.L., et al. Antibody specificities for PSA and PSA fragments by SDS-PAGE Western blot analysis. Tumor Biol. 20:(Suppl 1):1999;79-85.
16. Finlay J.A., Day J.R., Rittenhouse H.G. Polyclonal and monoclonal antibodies to prostate-specific antigen can cross-react with human kallikrein 2 and human kallikrein 1. Urology. 53:1999;746-751.
17. Kumar A., Mikolajczyk S.D., Goel A.S., et al. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. 57:1997;3111-3114.
18. Mikolajczyk S.D., Millar L.S., Kumar A., et al. Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1. Int J Cancer. 81:1999;438-442.
19. Berry S.J., Coffey D.S., Walsh P.C., et al. The development of human benign prostatic hyperplasia with age. J Urol. 132:1984;474-479.
20. McNeal J.E. Origin and evolution of benign prostatic enlargement. Invest Urol. 15:1978;340-345.
21. Roehrborn C.G., Boyle P., Gould A.L., et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 53:1999;581-589.
22. Babaian R.J., Fritsche H.A., Evans R.B. Prostate-specific antigen and prostate gland volume correlation and clinical application . J Clin Lab Anal. 4:1990;135-137.